High-Risk Human Papillomavirus Detection via Cobas<sup>®</sup> 4800 and REBA HPV-ID<sup>®</sup> Assays
Issued Date
2022-12-01
Resource Type
eISSN
19994915
Scopus ID
2-s2.0-85144537975
Pubmed ID
36560717
Journal Title
Viruses
Volume
14
Issue
12
Rights Holder(s)
SCOPUS
Bibliographic Citation
Viruses Vol.14 No.12 (2022)
Suggested Citation
Liewchalermwong S., Oranratanaphan S., Termrungruanglert W., Triratanachat S., Tantbirojn P., Kitkumthorn N., Bhattarakosol P., Chaiwongkot A. High-Risk Human Papillomavirus Detection via Cobas<sup>®</sup> 4800 and REBA HPV-ID<sup>®</sup> Assays. Viruses Vol.14 No.12 (2022). doi:10.3390/v14122713 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/84837
Title
High-Risk Human Papillomavirus Detection via Cobas<sup>®</sup> 4800 and REBA HPV-ID<sup>®</sup> Assays
Other Contributor(s)
Abstract
Persistent infection with high-risk human papillomaviruses (HR-HPVs), particularly HPV16 and 18, has long been known to induce cervical cancer progression. However, given that a minority of HPV-infected women develop cancer, analysis of HR-HPV-infected women could help to predict who is at risk of acquiring cervical cancer. Therefore, to improve HR-HPVs detection, we used the FDA-approved cobas® 4800 HPV and REBA HPV-ID® HPV assays to detect HR-HPVs in colposcopy-derived cervical cells from 303 patients, detecting 72.28% (219) and 71.62% (217) of HR-HPVs positive cases, with HPV16 detection rates of 35.64% (108) and 30.69% (93), respectively. Of the HPV16-positive cases, cobas® 4800 and REBA HPV-ID® identified 28.81% (51) and 25.42% (45) of the CIN1 cases, and 55% (33) and 50% (30) of the 60 CIN2/3 cases, respectively. HPV-diagnostic concordance was 82.17% overall (kappa = 0.488), 87.45% for HR-HPVs (kappa = 0.689), and 88.33% for CIN2/3 (kappa = 0.51). The HR-HPVs detection rates of these assays were comparable. Our findings reveal that the FDA-approved HR-HPVs detection assay is appropriate for screening women with HR-HPVs infection, and for predicting increased risk of cervical cancer progression. REBA HPV-ID® can be used to detect low risk-HPV types in high-grade cervical lesions that are HR-HPV negative as well as in the distribution of HPV types.